echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Int J Urol: Which is better, radical prostatectomy or external radiation therapy + androgen deprivation therapy in patients with clinical T3b prostate cancer?

    Int J Urol: Which is better, radical prostatectomy or external radiation therapy + androgen deprivation therapy in patients with clinical T3b prostate cancer?

    • Last Update: 2022-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Prostate cancer is the most common cancer in men and is most common in men between the ages of 60 and 70
    .


    Definite treatments for prostate cancer include radical prostatectomy and external radiation therapy, and the optimal treatment of prostate tumors is currently unknown due to the lack of definitive and well-established randomized controlled trials


    Definite treatments for prostate cancer include radical prostatectomy and external radiation therapy.


    Here, researchers from Hallym University Dongtan Sacred Heart Hospital in South Korea compared the oncological outcomes of patients with clinical T3b prostate cancer who received either radical prostatectomy (RP) or radiotherapy plus androgen deprivation therapy (HT + RT)
    .


    The findings were published in the International Journal of Urology


    compared oncological outcomes in patients with clinical T3b prostate cancer who underwent radical prostatectomy (RP) or radiotherapy plus androgen deprivation therapy (HT+RT) compared patients with clinical T3b prostate cancer who underwent radical prostatectomy (RP) or radiotherapy Oncologic Outcomes of Plus Androgen Deprivation Therapy (HT+RT)

    The researchers evaluated men with clinical T3b prostate cancer who received RP or HT + RT between 2007 and 2014
    .


    All patients were relatively healthy, with Eastern Cooperative Oncology Group performance status of 0 or 1, and no nodules or distant metastases


    Results showed that of 152 patients with clinical T3b prostate cancer between 2007 and 2014, 45 received RP and 107 received HT+RT
    .


    The mean cancer-specific survival in the RP group was significantly longer than in the HT+RT group (P = 0.


    (a) Kaplan-Meier analysis of crpc-free survival in patients treated with RP and HT + RT in a propensity score-matched population (P = 0.
    053)
    .


    (b) Kaplan-Meier analysis of overall survival in a propensity score-matched population treated with RP and HT + RT (P = 0.


    (a) Kaplan-Meier analysis of crpc-free survival in patients treated with RP and HT + RT in a propensity score-matched population (P = 0.


    Cancer-specific survival in men with clinical T3b prostate cancer who received RP was significantly longer than in those who received HT+RT, suggesting that RP could be a better final treatment option for these patients.


    Original source:

    Wonchul Lee, Bumjin Lim, Yoon Soo Kyung et al.


     

    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.